Floatz logo

Donanemab

Nervous System Diseases

Eli Lilly and Companymonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

34 Active assets in the Nervous System Diseases cohort.

Asset / SponsorPhaseRating
Guanfacine
Maimonides Medical Center
Phase 4BB
Ginkgolide
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 4BB
Guanfacine
Maimonides Medical Center
Phase 4BB
Opc-34712
Otsuka Pharmaceutical Development & Commercialization, Inc.
Phase 3BB
3-N-BUTYLPHTHALIDE
Qianfoshan Hospital
Phase 4BB

View all 50 →

Same molecule, other indications

Donanemab is also rated in:

Alzheimer diseaseDormant
BB
Indicative ·
70 / 100
View asset →
Down syndromeDormant
BB
Indicative ·
65 / 100
View asset →
APP-related brain and vascular amyloidosisDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →